MCID: MCN008
MIFTS: 39

Mucinous Cystadenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Mucinous Cystadenocarcinoma

MalaCards integrated aliases for Mucinous Cystadenocarcinoma:

Name: Mucinous Cystadenocarcinoma 12 15 17
Cystadenocarcinoma, Mucinous 44 70
Pseudomucinous Cystadenocarcinoma 12
Cystadenocarcinoma Mucinous 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3603
MeSH 44 D018282
NCIt 50 C3776
SNOMED-CT 67 79143006
UMLS 70 C0206699

Summaries for Mucinous Cystadenocarcinoma

Disease Ontology : 12 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue, with a capsulated structure and mucus-producing cells.

MalaCards based summary : Mucinous Cystadenocarcinoma, also known as cystadenocarcinoma, mucinous, is related to ovarian mucinous cystadenocarcinoma and appendix adenocarcinoma. An important gene associated with Mucinous Cystadenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Cytoskeletal Signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Bevacizumab and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, appendix and ovary.

Wikipedia : 73 Mucinous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Related Diseases for Mucinous Cystadenocarcinoma

Diseases related to Mucinous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 425)
# Related Disease Score Top Affiliating Genes
1 ovarian mucinous cystadenocarcinoma 32.4 VIM FSHR CEACAM5
2 appendix adenocarcinoma 30.9 SMAD4 KRT7 KRT20
3 appendiceal neoplasm 30.5 KRT7 CEACAM5
4 ovarian brenner tumor 30.5 KRT7 KRT20
5 teratoma 30.4 KRT7 KRT20 CEACAM5 ACTC1
6 benign giant cell tumor 30.3 VIM PTPRC MUC1 ACTC1
7 spindle cell sarcoma 30.3 VIM MUC1 KRT7 ACTC1
8 goblet cell carcinoid 30.3 KRT20 CEACAM7
9 ovarian cystadenocarcinoma 30.3 SMAD4 MUC16 MUC1 CEACAM5
10 hemangiopericytoma, malignant 30.3 VIM MUC1 ACTC1
11 krukenberg carcinoma 30.2 KRT7 KRT20 CEACAM5
12 ovarian mucinous neoplasm 30.2 KRT7 KRT20 CEACAM5
13 small cell carcinoma 30.2 PTPRC MUC1 KRT7 KRT20
14 papillary carcinoma 30.1 MUC1 KRT7 KRT20
15 adenoma 30.1 SMAD4 MUC1 KRT7 KRT20
16 angiosarcoma 30.1 VIM PDPN MUC1 KRT7
17 rhabdoid cancer 30.1 VIM PTPRC MUC1 ACTC1
18 horseshoe kidney 30.1 KRT7 KRT20 ACTC1
19 benign teratoma 30.0 MUC1 KRT7 KRT20 CEACAM5
20 collecting duct carcinoma 30.0 VIM MUC1 KRT7 KRT20
21 mucoepidermoid carcinoma 29.9 MUC2 MUC1 KRT7 CEACAM5
22 papillary cystadenocarcinoma 29.9 MUC16 KRT7 KRT20
23 mucinous ovarian cystadenoma 29.9 KRT7 KRT20 CEACAM5
24 intestinal obstruction 29.8 KRT7 KRT20 CEACAM5
25 mucinous adenocarcinoma 29.8 VIM MUC16 MUC1 KRT7 KRT20 CEACAM5
26 lymphangioma 29.7 VIM PDPN CEACAM5 ACTC1
27 cystadenoma 29.6 MUC16 MUC1 KRT7 KRT20 CEACAM5 CEACAM3
28 adenocarcinoma 29.6 SMAD4 MUC1 KRT7 KRT20 CEACAM5
29 wilms tumor 1 29.6 VIM PTPRC PDPN MUC1 KRT7 ACTC1
30 rhabdomyosarcoma 29.6 VIM SMAD4 PTPRC KRT7 ACTC1
31 pseudomyxoma peritonei 29.6 MUC2 MUC16 MUC1 KRT7 KRT20 CEACAM5
32 ovarian mucinous adenocarcinoma 29.5 MUC2 KRT7 KRT20 CEACAM5
33 cystadenocarcinoma 29.5 VIM PTPRC PDPN MUC2 MUC16 MUC1
34 neuroendocrine carcinoma 29.5 PTPRC MUC1 KRT7 KRT20 CEACAM5
35 benign mesothelioma 29.4 VIM PDPN KRT7 KRT20 CEACAM5
36 ovarian serous cystadenocarcinoma 29.4 MUC16 FSHR CEACAM5
37 endodermal sinus tumor 29.4 VIM MUC16 KRT7 CEACAM5
38 colon adenocarcinoma 29.3 SMAD4 KRT20 CEACAM7 CEACAM5
39 signet ring cell adenocarcinoma 29.3 PDPN MUC2 MUC1 KRT7 KRT20 CEACAM5
40 clear cell adenocarcinoma 29.3 SMAD4 MUC16 KRT7 KRT20
41 papillary adenocarcinoma 29.0 VIM MUC16 MUC1 KRT7 CEACAM5 CEACAM3
42 endometrial cancer 28.7 SMAD4 MUC16 MUC1 KRT7 KRT20 CEACAM5
43 lung cancer susceptibility 3 28.7 SMAD4 MUC16 MUC1 KRT7 KRT20 CEACAM7
44 polycystic liver disease 1 with or without kidney cysts 28.5 MUC16 MUC1 KRT7 KRT20 CEACAM5 CEACAM3
45 pancreatic cancer 28.0 SMAD4 MUC2 MUC16 MUC1 KRT7 KRT20
46 lung mucinous cystadenocarcinoma 11.6
47 mucinous cystadenocarcinoma of the pancreas 11.5
48 appendix mucinous cystadenocarcinoma 11.3
49 breast mucinous cystadenocarcinoma 11.3
50 pancreatic non-invasive mucinous cystadenocarcinoma 11.3

Graphical network of the top 20 diseases related to Mucinous Cystadenocarcinoma:



Diseases related to Mucinous Cystadenocarcinoma

Symptoms & Phenotypes for Mucinous Cystadenocarcinoma

Drugs & Therapeutics for Mucinous Cystadenocarcinoma

Drugs for Mucinous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
3
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
4 Antibodies Phase 3
5 Antineoplastic Agents, Immunological Phase 3
6 Immunoglobulins, Intravenous Phase 3
7 Immunoglobulins Phase 3
8 Angiogenesis Inhibitors Phase 3
9 Antibodies, Monoclonal Phase 3
10 Antimetabolites Phase 3
11 Immunoglobulin G Phase 3
12 Mitogens Phase 3
13 Endothelial Growth Factors Phase 3
14
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
15
Belinostat Approved, Investigational Phase 2 866323-14-0
16
Ipilimumab Approved Phase 2 477202-00-9
17
nivolumab Approved Phase 2 946414-94-4
18
Gemcitabine Approved Phase 2 95058-81-4 60750
19
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
20
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
21
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
22
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
23
Lenograstim Approved, Investigational Phase 2 135968-09-1
24
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
25
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
26
Molgramostim Investigational Phase 2 99283-10-0
27
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
28 Protein Kinase Inhibitors Phase 2
29 Histone Deacetylase Inhibitors Phase 2
30 Anti-Infective Agents Phase 2
31 Antiviral Agents Phase 2
32 Immunologic Factors Phase 2
33 Tubulin Modulators Phase 2
34 Albumin-Bound Paclitaxel Phase 2
35 Antimitotic Agents Phase 2
36 topoisomerase I inhibitors Phase 2
37 Alkylating Agents Phase 2
38 Adjuvants, Immunologic Phase 2
39 Antirheumatic Agents Phase 2
40 Immunosuppressive Agents Phase 2
41
Denileukin diftitox Approved, Investigational Phase 1 173146-27-5
42
Bortezomib Approved, Investigational Phase 1 179324-69-7 93860 387447
43
Docetaxel Approved, Investigational Phase 1 114977-28-5 148124
44
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
45
Ethanol Approved Phase 1 64-17-5 702
46
Glutamic acid Approved, Nutraceutical Phase 1 56-86-0 33032
47
Paclitaxel poliglumex Experimental, Investigational Phase 1 263351-82-2
48
Veliparib Investigational Phase 1 912444-00-9 11960529
49 Analgesics, Non-Narcotic Phase 1
50 Analgesics Phase 1

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
2 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
3 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
4 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
5 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
6 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
7 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
8 A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
9 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
10 Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer Completed NCT00357448 Phase 1
11 A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (NSC #704865) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00079430 Phase 1 paclitaxel;carboplatin
12 A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of CT-2103 and Carboplatin (NSC #214240) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
13 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
14 A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
15 PHASE I STUDY OF PACLITAXEL COMBINED WITH TOPOTECAN AND CISPLATIN AND G-CSF IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN EPITHELIAL MALIGNANCIES Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
16 A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
17 A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
18 A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
19 A Phase I Study of ABT-888 in Combination With Oxaliplatin and Capecitabine in Advanced Solid Tumors Terminated NCT01233505 Phase 1 veliparib;capecitabine;oxaliplatin
20 EUS Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm Terminated NCT01525706 Phase 1 Ethanol and Paclitaxel Injection
21 Non-invasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis by Quantitative Real Time MEMO-PCR Unknown status NCT02130648
22 A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT01080521
23 A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer Active, not recruiting NCT02111941 Early Phase 1
24 Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy Terminated NCT01275664 Aprepitant;Carboplatin;Cisplatin;Dexamethasone;Granisetron Transdermal Patch

Search NIH Clinical Center for Mucinous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, mucinous

Genetic Tests for Mucinous Cystadenocarcinoma

Anatomical Context for Mucinous Cystadenocarcinoma

MalaCards organs/tissues related to Mucinous Cystadenocarcinoma:

40
Pancreas, Appendix, Ovary, Endothelial, Colon, Testis, Lymph Node

Publications for Mucinous Cystadenocarcinoma

Articles related to Mucinous Cystadenocarcinoma:

(show top 50) (show all 696)
# Title Authors PMID Year
1
Anaplastic carcinoma of the pancreas associated with a mucinous cystic adenocarcinoma. A case report and review of the literature. 61 54
17993730 2007
2
[Two cases of appendicial mucinous cystadenocarcinoma with raised serum and mucin carcinoembryonic antigen (CEA) concentration]. 54 61
12833863 2003
3
Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. 54 61
9852392 1999
4
Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. 54 61
7543441 1995
5
Serum and tissue measurements of CA72-4 in ovarian cancer patients. 54 61
8381375 1993
6
CA54/61 as a marker for epithelial ovarian cancer. 54 61
1737381 1992
7
A case of primary mucinous cystadenocarcinoma of the appendix with elevated serum carcinoembryonic antigen (CEA). 61 54
2101417 1990
8
miR‑224‑5p regulates the proliferation, migration and invasion of pancreatic mucinous cystadenocarcinoma by targeting PTEN. 61
33760113 2021
9
Primary Mucinous Cystadenocarcinoma of the Breast: A Rare Case Report With Review of Literature. 61
33635116 2021
10
Pulmonary Mucinous Cystadenoma - A Rare Pathology. 61
33402519 2021
11
Breast Metastases Secondary to Primary Pancreatic Mucinous Cystadenocarcinoma: A Case Report. 61
33370036 2021
12
Single-incision laparoscopic surgery compared to conventional laparoscopic surgery for appendiceal mucocele: a series of 116 patients. 61
33502619 2021
13
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. 61
33362915 2020
14
Autophagy promotes malignant migration and invasion via miR-224-5p/BCL2 in pancreatic mucinous cystadenocarcinoma MCC1 cells. 61
33029204 2020
15
Mucinous cystadenocarcinoma in the renal pelvis: primary or secondary? Case report and literature review. 61
31084406 2020
16
Mucinous cystadenocarcinoma of the oral tongue: malignant transformation from a mucinous cystadenoma? 61
33127690 2020
17
Pulmonary mucinous cystadenocarcinoma: an unusual presentation and literature review. 61
32675126 2020
18
Primary retroperitoneal mucinous cystadenocarcinoma with transition from the mesothelium. 61
33392473 2020
19
Clinical diagnosis and management of pancreatic mucinous cystadenoma and cystadenocarcinoma: Single-center experience with 82 patients. 61
32699579 2020
20
A Rare Case of Incidental Urachal Mucinous Cystadenocarcinoma. 61
32523832 2020
21
18F-FDG PET/CT Findings in a Patient With Primary Mucinous Cystadenocarcinoma of the Breast. 61
31876834 2020
22
Mammary synchronous mucinous cystadenocarcinoma and columnar cell mucinous carcinoma: a case report. 61
33042347 2020
23
Primary mucinous cystadenocarcinoma of the breast: a clinicopathologic analysis of one case and review of the literature. 61
33165376 2020
24
Incidental detection of microfilaria in cyst fluid of Mucinous cystadenocarcinoma of ovary: A rare case report. 61
32416487 2020
25
Role of Cross-sectional Imaging (CT/MRI) in Characterization and Distinguishing Benign from Malignant/Potentially Malignant Cystic Lesions of Pancreas. 61
32494507 2020
26
Mucinous Cystadenocarcinoma of the Pancreas with Cyst Infection in a Male Patient. 61
32999265 2020
27
A rare missense variant in APC interrupts splicing and causes AFAP in two Danish families. 61
32292534 2020
28
[A Case of Mucinous Cystoadenocarcinoma with Metastatic Liver Tumor in a Young Woman Lacking Specific Findings]. 61
32156954 2019
29
[Appendix Cancer with Long-Term Survival after Multimodality Therapy-A Case Report]. 61
32156998 2019
30
Metastatic mucinous cystadenocarcinoma of the pancreas presenting as intractable back pain. 61
31791983 2019
31
Surgery for cystic tumors of pancreas: Report of high-volume, multicenter Indian experience over a decade. 61
31543321 2019
32
Laparoscopic right colectomy associated with hyperthermic intraperitoneal chemotherapy as treatment for mucinous cystadenocarcinoma of the appendix - a video vignette. 61
31309644 2019
33
Impact of routine histopathological examination of appendectomy specimens on patient management: a study of 4012 appendectomy specimens. 61
32550328 2019
34
Etiologic Distribution of Pancreatic Cystic Lesions Identified on Computed Tomography/Magnetic Resonance Imaging. 61
31404022 2019
35
A 35 Year Old Bangladeshi Lady with Hereditary Mucinous Ovarian Cancer, Complicated with Omental Metastasis. 61
31086172 2019
36
[Primary mucinous cystadenocarcinoma of breast: report of a case]. 61
30955277 2019
37
Mucinous Cystadenoma of the Urachus and Review of Current Classification of Urachal Mucinous Cystic Neoplasms. 61
30398914 2019
38
Rare Breast Malignancy Subtypes: A Cytological, Histological, and Immunohistochemical Correlation. 61
31007516 2019
39
Urachal Mucinous Cystadenocarcinoma. 61
30674499 2019
40
Mucinous Cystadenocarcinoma of the Breast: Report of 2 Cases Including One With Long-Term Local Recurrence. 61
29745281 2018
41
Appendiceal mucinous cystadenocarcinoma with mural nodules of anaplastic carcinoma and K-RAS mutation. 61
30289401 2018
42
Contrast-enhanced Harmonic EUS Imaging of Pancreatic Mucinous Cystadenocarcinoma. 61
29780137 2018
43
Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. 61
29771769 2018
44
Mucinous breast carcinoma with tall columnar cells. 61
29658333 2018
45
[Mucinous cystadenocarcinoma of ovary associated with neuroendocrine carcinoma (Primary ovarian pulmonary-type small cell carcinoma): report of a case]. 61
29783809 2018
46
Mucinous cystadenocarcinoma arising from mucinous cystadenoma of the lung: case report and review of the literature. 61
29850162 2018
47
Adenocarcinoma classification: patterns and prognosis. 61
30259909 2018
48
Experience-based surgical approach to pancreatic mucinous cystic neoplasms with ovarian-type stroma. 61
29434957 2018
49
Sonographic Findings of Malignant Appendix Tumors in Seven Cases. 61
30065515 2018
50
Extremely large epithelial ovarian cancer associated with pregnancy: A case report. 61
29399351 2018

Variations for Mucinous Cystadenocarcinoma

Expression for Mucinous Cystadenocarcinoma

Search GEO for disease gene expression data for Mucinous Cystadenocarcinoma.

Pathways for Mucinous Cystadenocarcinoma

GO Terms for Mucinous Cystadenocarcinoma

Cellular components related to Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.7 VIM SLCO4A1 PTPRC PDPN MUC2 MUC16
2 apical plasma membrane GO:0016324 9.46 PDPN MUC1 CEACAM7 CEACAM5
3 Golgi lumen GO:0005796 8.8 MUC2 MUC16 MUC1

Biological processes related to Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.33 MUC2 MUC16 MUC1
2 intermediate filament organization GO:0045109 9.26 VIM KRT20
3 uterus development GO:0060065 8.96 SMAD4 FSHR
4 O-glycan processing GO:0016266 8.8 MUC2 MUC16 MUC1

Sources for Mucinous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....